| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 81, 2986-2993, Copyright © 1996 by Endocrine Society
ARTICLES |
O Torring, L Tallstedt, G Wallin, G Lundell, JG Ljunggren, A Taube, M Saaf and B Hamberger
Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden.
To analyze the benefits and risks of three common treatments, we randomly assigned 179 patients with Graves' hyperthyroidism as follows: 60 patients, 20-34 yr of age (young adults), received antithyroid drugs for 18 months (medical) or subtotal thyroidectomy (surgical), and 119 patients, 35-55 yr of age (old adults), received medical, surgical, or radioiodine (iodine-131) treatment. The follow-up time was at least 48 months. Antithyroid drugs, surgery, or iodine-131 treatment normalized the mean serum hormone levels within 6 weeks. The risk of relapse was highest in the medically treated young and old adults (42% vs. 34%), followed by that in those treated with iodine-131 (21%) and that in the surgically treated young and old adults (3% vs 8%), respectively. Elevated TSH receptor antibodies at the end of medical therapy or increasing TSH receptor antibodies values after medical or surgical treatment increased the probability of relapse. Development or worsening of ophthalmopathy was not associated with relapse per se. Ninety percent of the subjects in all groups were satisfied with the treatment they received. No significant difference in sick-leave due to Graves' or other diseases was seen during the first 2 yr after initiation of therapy. The increased risk of ophthalmopathy in patients with high serum T3 levels, especially when treated with iodine-131, and the relatively high frequency of relapse after treatment with antithyroid drugs are important factors to consider when selecting therapy for Graves' disease.
This article has been cited by other articles:
 |
|
 |
|
  F. Kaguelidou, C. Alberti, M. Castanet, M.-A. Guitteny, P. Czernichow, J. Leger, and for the French Childhood Graves' Disease Study Gro Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3817 - 3826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Brent Graves' Disease N. Engl. J. Med., June 12, 2008; 358(24): 2594 - 2605. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Laurberg, G. Wallin, L. Tallstedt, M. Abraham-Nordling, G. Lundell, and O. Torring TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study Eur. J. Endocrinol., January 1, 2008; 158(1): 69 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abraham-Nordling, G. Wallin, G. Lundell, and O. Torring Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves' disease Eur. J. Endocrinol., February 1, 2007; 156(2): 173 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Laurberg Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur. J. Endocrinol., December 1, 2006; 155(6): 783 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Radioiodine therapy for hyperthyroidism DTB, June 1, 2006; 44(6): 44 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Cooper Antithyroid Drugs N. Engl. J. Med., March 3, 2005; 352(9): 905 - 917. [Full Text] [PDF]
|
|
|
|
 |
|
 T.-C. Chao, J.-D. Lin, and M.-F. Chen Surgical Treatment of Thyroid Cancers With Concurrent Graves Disease Ann. Surg. Oncol., April 1, 2004; 11(4): 407 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Prabhakar, R. S. Bahn, and T. J. Smith Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy Endocr. Rev., December 1, 2003; 24(6): 802 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. Leslie, L. Ward, E. A. Salamon, S. Ludwig, R. C. Rowe, and E. A. Cowden A Randomized Comparison of Radioiodine Doses in Graves' Hyperthyroidism J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 978 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Y. Kim, Y. J. Park, D. J. Park, H.-K. Chung, W. B. Kim, L. D. Kohn, and B. Y. Cho Epitope Heterogeneity of Thyroid-Stimulating Antibodies Predicts Long-Term Outcome in Graves' Patients Treated with Antithyroid Drugs J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Mittendorf and C. R. McHenry Thyroidectomy for Selected Patients With Thyrotoxicosis Arch Otolaryngol Head Neck Surg, January 1, 2001; 127(1): 61 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Escobar-Jiménez, M L Férnandez-Soto, V Luna-López, M Quesada-Charneco, and D Glinoer Trends in diagnostic and therapeutic criteria in Graves' disease in the last 10 years Postgrad. Med. J., June 1, 2000; 76(896): 340 - 344. [Abstract] [Full Text]
|
|
|
|
|
|
O. Sabri, M. Zimny, G. Schulz, M. Schreckenberger, P. Reinartz, K. Willmes, and U. Buell Success Rate of Radioiodine Therapy in Graves' Disease: The Influence of Thyrostatic Medication J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1229 - 1233. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. S. Cooper Radioiodine for Hyperthyroidism: Where Do We Stand After 50 Years? JAMA, July 22, 1998; 280(4): 375 - 376. [Full Text] [PDF]
|
|
|
|
 |
|
 TREATMENT OF GRAVES' HYPERTHYROIDISM Journal Watch (General), September 13, 1996; 1996(913): 3 - 3. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
